In silico predictions of target clinical efficacy

Drug Discovery Today: TARGETS

Volumn 3, Issue 5, 2004, Pages 216-222

  Friedrich, Christina M ^a   Paterson, Thomas S ^a  

^a Entelos Inc   (United States)

Author keywords

Bioinformatics; Biological model; Computer simulation; Drug Discovery; Pharmaceutical Science; Risk management; Top down modeling; Virtual patient

Indexed keywords

UNCLASSIFIED DRUG;

BIOLOGICAL MODEL; CELL TYPE; COMPUTER ANALYSIS; COMPUTER MODEL; COST BENEFIT ANALYSIS; DISEASE COURSE; DISEASE MODEL; DRUG EFFICACY; DRUG SCREENING; DRUG TARGETING; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HYPOTHESIS; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PATIENT; PREDICTION; QUANTITATIVE ANALYSIS; REVIEW; RISK REDUCTION; TECHNIQUE; TECHNOLOGY; TIME; TREATMENT FAILURE; UPREGULATION; VALIDATION PROCESS;

EID: 4644249962     PISSN: 17418372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1741-8372(04)02451-X     Document Type: Review

References (13)

1. DiMasi J.A. Risks in new drug development: approval success rates for investigational drugs. Clin. Pharmacol. Ther. 69:2001;297-307
2. DiMasi J.A. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics. 20:(Suppl. 3):2002;1-10
3. Sheiner L.B. Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 61:1997;275-291
4. Sheiner L.B., Steimer J.L. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu. Rev. Pharmacol. Toxicol. 40:2000;67-95
5. Hausheer F.H., et al. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent. Cancer Chemother. Pharmacol. 52:(Suppl. 1):2003;S3-S15
6. Bangs A., Paterson T. Finding value in in silico biology. Biosilico. 1:2003;18-22
7. Scherrer D., et al. Assessing the impact of biosimulation on target selection and validation. Biosilico. 1:2003;184-188
8. Balant L.P., Gex-Fabry M. Modelling during drug development. Eur. J. Pharm. Biopharm. 50:2000;13-26
9. Rowland, M. et al (2004). Physiologically based pharmacokinetics in drug development and regulatory science: A workshop report. AAPS PharmSci. 6, Article 6 (http://www.aapspharmsci.org/ps0601/ps060106/ps060106.pdf)
10. Ferber G. Biomarkers and proof of concept. Methods Find. Exp. Clin. Pharmacol. 24:2002;35-40
11. Michelson S., Okino M. The virtual patient: capturing patient variability using biosimulation. Preclinica. 2:2004;33-37
12. Colburn W.A., Lee J.W. Biomarkers, validation and pharmacokinetic- pharmacodynamic modeling. Clin. Pharmacokinet. 42:2003;997-1022
13. Lathia C.D. Biomarkers and surrogate endpoints: how and when might they impact drug development? Dis. Markers. 18:2002;83-90